Thomas B.
- Country
- France
- Department
- Medical Oncology department
Research Overview
- Phase III Randomized Double‑Blind Study of Alpelisib Plus Trastuzumab and Pertuzumab Maintenance Therapy in HER2‑Positive Advanced Breast Cancer with PIK3CA Mutation
- TAILORswitch (PADA-2): ctDNA‑guided switch to camizestrant plus abemaciclib in ER‑positive HER2‑negative metastatic breast cancer
- Efficacy and Safety of Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib in ER+/HER2- Advanced Breast Cancer with ESR1 Mutation
Data & Insights
Has run more than one trial at 413 of 696 partner sites.
Specializations
HER2-Positive Breast Cancer
This investigator specializes in treating HER2-positive breast cancer across various stages, including early-stage, locally advanced, and metastatic disease. Their research encompasses novel therapeutic approaches using targeted antibody-drug conjugates and combination therapies.
- Brain Metastasis Management
- Adjuvant Therapy Optimization
- Advanced Disease Treatment
Hormone Receptor-Positive Disease
The investigator focuses on advancing treatment for HR-positive/HER2-negative breast cancer, exploring innovative combinations of endocrine therapy with targeted agents. Their work includes studies on resistance mechanisms and novel therapeutic strategies.
- ESR1 Mutation Detection
- CDK4/6 Inhibitor Therapies
- Biomarker-Driven Treatment
Advanced Treatment Approaches
Research initiatives include investigating circulating tumor DNA for early detection and treatment monitoring, along with studies of immunotherapy combinations and novel therapeutic agents for various breast cancer subtypes.
- Molecular Relapse Detection
- Triple-Negative Breast Cancer
- Precision Medicine Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.